Document is current
Any future updates will be listed below
-
Authors
Pandeya, Nirmala
Huang, Nancy
Jiyad, Zainab https://orcid.org/0000-0001-9677-8885
Plasmeijer, Elsemieke I. https://orcid.org/0000-0002-8846-1930
Way, Mandy https://orcid.org/0000-0003-3444-1907
Isbel, Nicole https://orcid.org/0000-0002-9566-7179
Campbell, Scott https://orcid.org/0000-0003-1338-2151
Chambers, Daniel C. https://orcid.org/0000-0002-9553-5870
Hopkins, Peter https://orcid.org/0000-0003-3261-9345
Soyer, H. Peter https://orcid.org/0000-0002-4770-561X
Whiteman, David C. https://orcid.org/0000-0003-2563-9559
Olsen, Catherine M.
Green, Adele C. https://orcid.org/0000-0002-2753-4841
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (552429)
National Health and Medical Research Council (552429)
National Health and Medical Research Council (552429)
National Health and Medical Research Council (552429)
- License Information
-
More Information
Article History
Received: 6 April 2022
Revised: 21 September 2022
Accepted: 11 October 2022
First Online: 25 October 2022
Declarations
:
: HPS is a shareholder of MoleMap NZ Limited and e-derm consult GmbH, and undertakes regular teledermatological reporting for both companies. HPS is a Medical Consultant for Canfield Scientific Inc, MoleMap Australia Pty Ltd, Blaze Bioscience Inc, Revenio Research Oy and a Medical Advisor for First Derm. All other authors state no conflicts of interest.
: Provided.
